- Home
- TSI vs SERA Comparison
TSI vs SERA Comparison
Compare TSI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- SERA
- Stock Information
- Founded
- TSI 1987
- SERA 2008
- Country
- TSI United States
- SERA United States
- Employees
- TSI N/A
- SERA N/A
- Industry
- TSI Investment Managers
- SERA Precision Instruments
- Sector
- TSI Finance
- SERA Health Care
- Exchange
- TSI Nasdaq
- SERA Nasdaq
- Market Cap
- TSI 244.7M
- SERA 258.3M
- IPO Year
- TSI N/A
- SERA 2021
- Fundamental
- Price
- TSI $5.08
- SERA $7.49
- Analyst Decision
- TSI
- SERA
- Analyst Count
- TSI 0
- SERA 0
- Target Price
- TSI N/A
- SERA N/A
- AVG Volume (30 Days)
- TSI 106.8K
- SERA 132.8K
- Earning Date
- TSI 01-01-0001
- SERA 11-06-2024
- Dividend Yield
- TSI 7.46%
- SERA N/A
- EPS Growth
- TSI N/A
- SERA N/A
- EPS
- TSI N/A
- SERA N/A
- Revenue
- TSI N/A
- SERA $107,000.00
- Revenue This Year
- TSI N/A
- SERA N/A
- Revenue Next Year
- TSI N/A
- SERA $2,020.00
- P/E Ratio
- TSI N/A
- SERA N/A
- Revenue Growth
- TSI N/A
- SERA N/A
- 52 Week Low
- TSI $4.48
- SERA $1.56
- 52 Week High
- TSI $4.87
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- TSI 55.39
- SERA 49.26
- Support Level
- TSI $5.05
- SERA $6.25
- Resistance Level
- TSI $5.17
- SERA $7.27
- Average True Range (ATR)
- TSI 0.06
- SERA 0.46
- MACD
- TSI -0.00
- SERA -0.06
- Stochastic Oscillator
- TSI 70.59
- SERA 46.91
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.